Endometrial endometrioid adenocarcinoma
MONDO:0006192A primary endometrial adenocarcinoma composed of neoplastic cells that form complex glandular patterns associated with budding and branching of the neoplastic glands. The neoplastic glands resemble those of the normal endometrium and may or may not be associated with sheet-like proliferation of malignant cells. Endometrioid adenocarcinoma is the most commonly seen morphologic variant of endometrial adenocarcinoma.
Also known as: endometrial endometrioid adenocarcinoma, endometrioid adenocarcinoma of endometrium, endometrioid adenocarcinoma of the endometrium, endometrioid carcinoma of endometrium, endometrioid carcinoma of the endometrium, endometrioid endomet. adenocar., endometrioid endometrial adenocarcinoma, uterine corpus endometrioid adenocarcinoma
2892 clinical trials for this condition and its sub-types, 55 tagged with Endometrial endometrioid adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Endometrial endometrioid adenocarcinoma
-
New pill could shrink uterine cancer without surgery
Disease control CompletedThis phase II trial is testing an oral drug called giredestrant in 30 people with grade 1 endometrial cancer. The goal is to see if the drug can shrink or control the cancer over 6 months. Participants take one pill daily for up to 24 cycles, and doctors monitor tumor changes and…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Hormone blockers join forces against Treatment-Resistant endometrial cancer
Disease control CompletedThis phase II trial tests whether combining two hormone-blocking drugs — onapristone and anastrozole — can shrink tumors or slow cancer growth in women with hormone-receptor-positive endometrial cancer that has not responded to prior chemotherapy. Onapristone blocks progesterone …
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control CompletedThis phase II trial tested whether combining two drugs, pembrolizumab and olaparib, could help people with persistent or recurrent endometrial cancer or carcinosarcoma. The study enrolled 26 participants and looked at how many responded to treatment and what side effects occurred…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug cocktail shows promise in slowing uterine cancer before surgery
Disease control CompletedThis early-phase trial tested two drugs, abemaciclib and letrozole, given before standard hysterectomy in 27 women with endometrial cancer. The goal was to see if the combination could slow cancer cell growth by measuring changes in a protein called Ki-67. The study was small and…
Early phase 1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could a cancer drug shrink endometrial tumors?
Disease control CompletedThis phase 2 trial tested the drug cabozantinib in 102 women with endometrial cancer that had returned or spread. The drug works by blocking enzymes that help tumors grow and by cutting off their blood supply. Researchers measured how many patients saw their tumors shrink or stop…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Remote strength training aims to boost endometrial cancer survivorship in rural areas
Symptom relief CompletedThis study tests a 10-week, remotely supervised strength training program for endometrial cancer survivors living in rural or underserved areas. The goal is to see if the program is practical and helps improve physical function and quality of life. Participants exercise twice a w…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC